Search





Search





Markets
/
Stocks
/
fdmt
/

4D Molecular Therapeutics Inc

FDMT

Add to Watchlist

10.180USD

+0.110+1.09%

Close 07-31 16:00（ET）Quotes delayed by 15 min

532.17MMarket Cap

LossP/E TTM

4D Molecular Therapeutics Inc

10.180

+0.110+1.09%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

FDMT Cash Flow Statement

You can access the annual and quarterly cash flow statements of 4D Molecular Therapeutics Inc to evaluate its financial soundness and stability.

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

FY2021Q1

FY2020Q4

FY2019Q4

FY2019Q3

Operating cash flows (indirect method)

Cash flow from continuing operating activities

-42.65%-68.13M

162.25%28.55M

-58.20%-46.50M

-43.43%-43.38M

-64.18%-47.76M

-86.06%-45.86M

-2409.91%-29.39M

-37.06%-30.24M

-4.24%-29.09M

-10.97%-24.65M

94.43%-1.17M

-10.86%-22.07M

-18.50%-27.91M

-1.73%-22.21M

-33.69%-21.02M

-22.83%-19.90M

-53.20%-23.55M

-24.78%-21.84M

---15.72M

---16.20M

---15.37M

-101.46%-17.50M

---8.69M

---10.86M

Net income from continuing operations

-43.33%-68.76M

139.05%19.40M

-29.73%-56.88M

-56.38%-54.66M

-48.06%-47.97M

-53.86%-49.67M

-327.49%-43.84M

-18.02%-34.95M

-12.97%-32.40M

-17.91%-32.28M

60.08%-10.26M

-5.45%-29.62M

-8.90%-28.68M

-9.15%-27.38M

-15.52%-25.69M

-270.09%-28.09M

-60.54%-26.34M

-22.08%-25.08M

---22.24M

---7.59M

---16.41M

-27.50%-20.55M

---16.11M

---16.68M

Operating gains losses

-27.65%1.27M

-31.84%1.22M

-25.95%1.26M

-28.20%1.17M

10.04%1.75M

17.91%1.78M

21.99%1.70M

13.73%1.62M

12.89%1.59M

9.01%1.51M

58.82%1.40M

71.84%1.43M

80.56%1.41M

-26.44%1.39M

130.10%879.00K

124.59%831.00K

105.25%782.00K

408.63%1.89M

--382.00K

--370.00K

--381.00K

16.67%371.00K

--318.00K

--280.00K

Other non-cash items

72.53%-348.00K

79.30%-383.00K

81.42%-412.00K

80.80%-444.00K

-72.38%-1.27M

-304.81%-1.85M

-1632.81%-2.22M

-1068.18%-2.31M

-97.05%-735.00K

-117.62%-457.00K

-149.04%-128.00K

-140.33%-198.00K

-161.75%-373.00K

-128.38%-210.00K

1086.36%261.00K

2131.82%491.00K

2645.45%604.00K

1441.67%740.00K

--22.00K

-98.16%48.00K

--2.61M

--5.14M

Change in working capital

33.75%-4.75M

174.10%2.75M

-40.93%5.00M

912.35%5.59M

-103.72%-7.17M

-659.94%-3.72M

173.18%8.46M

-150.63%-688.00K

21.62%-3.52M

285.47%664.00K

417.09%3.10M

-46.43%1.36M

-76.95%-4.49M

88.49%-358.00K

-144.73%-977.00K

119.79%2.54M

-41.63%-2.54M

-442.40%-3.11M

--2.18M

---12.82M

---1.79M

-73.61%908.00K

--3.44M

---646.00K

-Change in receivables

----

--0.00

-100.00%0.00

100.00%0.00

-90.98%47.00K

226.10%744.00K

--427.00K

---253.00K

--521.00K

-637.50%-590.00K

---80.00K

--263.00K

-Change in prepaid expenses

-271.79%-3.99M

-165.74%-3.17M

50.82%2.75M

205.85%1.07M

18.76%-1.07M

-634.08%-1.19M

258.85%1.82M

-78.41%-1.01M

-1568.89%-1.32M

109.07%223.00K

-211.04%-1.15M

-134.39%-565.00K

-91.15%90.00K

54.50%-2.46M

97.14%1.03M

1469.17%1.64M

31.57%1.02M

-246.50%-5.40M

--524.00K

---120.00K

--773.00K

-207.89%-1.56M

--1.45M

---1.91M

-Change in other current assets

75.92%-670.00K

113.75%192.00K

101.83%10.00K

-51.61%-2.35M

-3061.36%-2.78M

-139500.00%-1.40M

-689.86%-545.00K

-1507.27%-1.55M

20.00%-88.00K

-100.23%-1.00K

84.70%-69.00K

--110.00K

---110.00K

--440.00K

---451.00K

----

--0.00

-100.00%0.00

--89.00K

---9.00K

-Change in other current liabilities

9957.14%1.38M

---90.00K

-2900.00%-90.00K

-200.00%-15.00K

-118.18%-14.00K

-100.00%0.00

98.47%-3.00K

97.92%-5.00K

125.84%77.00K

101.52%19.00K

60.80%-196.00K

-47.24%-240.00K

75.55%-298.00K

-454.55%-1.25M

19.35%-500.00K

98.79%-163.00K

-17.78%-1.22M

-85.70%352.00K

---620.00K

---13.42M

---1.03M

334.25%2.46M

---1.05M

--358.00K

Cash from non-recurring investing activities

Cash from operating activities

-42.65%-68.13M

162.25%28.55M

-58.20%-46.50M

-43.43%-43.38M

-64.18%-47.76M

-86.06%-45.86M

-2409.91%-29.39M

-37.06%-30.24M

-4.24%-29.09M

-10.97%-24.65M

94.43%-1.17M

-10.86%-22.07M

-18.50%-27.91M

-1.73%-22.21M

-33.69%-21.02M

-22.83%-19.90M

-53.20%-23.55M

-24.78%-21.84M

---15.72M

---16.20M

---15.37M

-101.46%-17.50M

---8.69M

---10.86M

Investing cash flow

Net cash from continuing investing activities

-101.74%-11.00K

-107.38%-70.00K

-105.12%-91.00K

-81.09%66.00K

-11.13%631.00K

72.86%949.00K

339.01%1.78M

-56.65%349.00K

-29.84%710.00K

-49.77%549.00K

-79.38%405.00K

-61.04%805.00K

-84.22%1.01M

-78.55%1.09M

-25.46%1.96M

180.33%2.07M

898.91%6.41M

903.15%5.10M

--2.63M

--737.00K

--642.00K

6.50%508.00K

--477.00K

--1.06M

Capital expenditures

----

-81.09%66.00K

-11.13%631.00K

72.86%949.00K

339.01%1.78M

-56.65%349.00K

-29.84%710.00K

-49.77%549.00K

-79.38%405.00K

-61.04%805.00K

-84.22%1.01M

-78.55%1.09M

-25.46%1.96M

180.33%2.07M

898.91%6.41M

903.15%5.10M

--2.63M

--737.00K

--642.00K

6.50%508.00K

--477.00K

--1.06M

Net cash flow from disposal of fixed assets

-101.74%-11.00K

-107.38%-70.00K

-105.12%-91.00K

-81.09%66.00K

-11.13%631.00K

72.86%949.00K

339.01%1.78M

-56.65%349.00K

-29.84%710.00K

-49.77%549.00K

-79.38%405.00K

-61.04%805.00K

-84.22%1.01M

-78.55%1.09M

-25.46%1.96M

180.33%2.07M

898.91%6.41M

903.15%5.10M

--2.63M

--737.00K

--642.00K

6.50%508.00K

--477.00K

--1.06M

Net cash flow from investment products

111.42%68.88M

-1709.85%-128.92M

-39.18%17.69M

81.16%-13.79M

112.41%32.58M

230.57%8.01M

-4.30%29.08M

-246.11%-73.19M

-694.78%-262.55M

82.32%-6.13M

75.29%30.39M

-15.86%50.09M

192.55%44.14M

-27.55%-34.69M

112.71%17.34M

--59.53M

---47.70M

---27.20M

---136.38M

----

Cash from non-current investing activities

Net cash flow from investing activities

115.63%68.89M

-1925.29%-128.85M

-34.88%17.78M

81.16%-13.85M

112.14%31.95M

205.64%7.06M

-8.94%27.30M

-249.20%-73.54M

-710.38%-263.26M

81.32%-6.68M

95.05%29.98M

-14.23%49.29M

179.71%43.13M

-10.80%-35.78M

111.06%15.37M

7897.56%57.47M

-8328.35%-54.11M

-6256.50%-32.29M

---139.01M

---737.00K

---642.00K

-6.50%-508.00K

---477.00K

---1.06M

Financing cash flow

Cash flow from continuous financing activities

--11.48M

18532.61%111.98M

-79.58%116.00K

-95.00%862.00K

----

-87.38%601.00K

-94.62%568.00K

-86.78%17.25M

2800.05%318.83M

132.75%4.76M

2195.00%10.56M

261138.00%130.52M

1647.85%10.99M

-98.24%2.05M

-76.73%460.00K

-106.10%-50.00K

174.26%629.00K

-43.62%116.14M

--1.98M

--820.00K

---847.00K

30842.99%205.98M

---670.00K

---1.46M

Net cash flow from common stock issuance/repurchase

--9.81M

20066.24%111.12M

-100.00%0.00

-94.76%860.00K

----

5.76%551.00K

-99.99%1.00K

-87.42%16.40M

3172.72%315.72M

48.01%521.00K

1805.73%8.98M

--130.38M

--9.65M

-99.69%352.00K

--471.00K

----

-44.06%114.73M

----

372810.91%205.10M

--55.00K

--0.00

Net cash flow from preferred stock issuance/repurchase

----

--0.00

----

--0.00

Proceeds from stock option exercised by employees

--1.67M

1632.00%866.00K

-79.54%116.00K

-99.76%2.00K

----

-98.82%50.00K

-45.48%567.00K

38.66%850.00K

119.84%3.11M

96.16%4.24M

380.32%1.04M

857.81%613.00K

61.83%1.42M

365.95%2.16M

-118.77%-371.00K

-92.20%64.00K

783.84%875.00K

-45.86%464.00K

--1.98M

--820.00K

--99.00K

--857.00K

----

Net cash flow from other financing activities

----

100.00%0.00

----

50.28%541.00K

-314.04%-472.00K

71.95%-69.00K

-149.47%-468.00K

--360.00K

---114.00K

74.00%-246.00K

4630.00%946.00K

--0.00

---946.00K

102.76%20.00K

---725.00K

---1.46M

Net cash from non-recurrent financing activities

Net cash from financing activities

--11.48M

18532.61%111.98M

-79.58%116.00K

-95.00%862.00K

----

-87.38%601.00K

-94.62%568.00K

-86.78%17.25M

2800.05%318.83M

132.75%4.76M

2195.00%10.56M

261138.00%130.52M

1647.85%10.99M

-98.24%2.05M

-76.73%460.00K

-106.10%-50.00K

174.26%629.00K

-43.62%116.14M

--1.98M

--820.00K

---847.00K

30842.99%205.98M

---670.00K

---1.46M

Net cash flow

Beginning cash balance

-59.66%60.24M

-74.11%48.55M

-59.19%77.16M

-51.55%133.53M

-40.05%149.34M

-31.97%187.54M

-19.99%189.06M

250.77%275.59M

375.84%249.11M

154.56%275.68M

108.23%236.31M

3.42%78.57M

-65.78%52.35M

19.02%108.30M

-53.44%113.48M

-70.77%75.97M

-44.71%153.00M

2.52%90.99M

--243.74M

--259.87M

--276.73M

49.21%88.75M

--59.48M

--72.87M

Current period cash flow changes

177.46%12.25M

130.59%11.69M

-1779.37%-28.60M

34.86%-56.37M

-159.69%-15.81M

-43.78%-38.20M

-103.87%-1.52M

-154.86%-86.53M

1.02%26.49M

52.51%-26.57M

859.10%39.37M

320.49%157.74M

134.04%26.22M

-190.22%-55.95M

96.60%-5.19M

332.69%37.51M

-356.86%-77.03M

-67.01%62.01M

---152.75M

---16.12M

---16.86M

2011.63%187.97M

---9.83M

---13.38M

Ending cash balance

-45.71%72.49M

-59.66%60.24M

-74.11%48.55M

-59.19%77.16M

-51.55%133.53M

-40.05%149.34M

-31.97%187.54M

-19.99%189.06M

250.77%275.59M

375.84%249.11M

154.56%275.68M

108.23%236.31M

3.42%78.57M

-65.78%52.35M

19.02%108.30M

-53.44%113.48M

-70.77%75.97M

-44.71%153.00M

--90.99M

--243.74M

--259.87M

457.33%276.73M

--49.65M

--59.48M

Free cash flow

-40.79%-68.13M

160.99%28.55M

-49.18%-46.50M

-42.01%-43.44M

-62.39%-48.39M

-85.77%-46.81M

-1877.73%-31.17M

-33.76%-30.59M

-3.04%-29.80M

-8.12%-25.20M

93.14%-1.58M

-4.10%-22.87M

3.49%-28.92M

13.46%-23.31M

-25.20%-22.98M

-29.68%-21.97M

-87.11%-29.96M

-49.56%-26.93M

---18.36M

---16.94M

---16.01M

-96.52%-18.01M

---9.16M

---11.92M

Currency unit

--USD

Audit opinions

----

FAQs

What is operating cash flow?



Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did 4D Molecular Therapeutics Inc Generate?



4D Molecular Therapeutics Inc generated -109.08M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did 4D Molecular Therapeutics Inc's Operating Cash Flow Change Year Over Year?



4D Molecular Therapeutics Inc's operating cash flow increased by 18.95% year over year.

What is investing cash flow?



Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does 4D Molecular Therapeutics Inc Spend on Capital Expenditures?



4D Molecular Therapeutics Inc spent 536.00K on capital expenditures in the most recent quarter。

What is financing cash flow?



Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has 4D Molecular Therapeutics Inc's Financing Cash Flow Changed?



4D Molecular Therapeutics Inc used 112.96M in financing activities in the latest quarter.

What is free cash flow and why does it matter for FDMT?



Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was 4D Molecular Therapeutics Inc’s free cash flow in the latest quarter?



Free cash flow was -109.62M reflecting a 20.78% change from the previous year.